Himchan Hospital Self-Plate Rich Plasma (PRP) intra-articular injection helps reduce pain and improve function
Sep 29, 2025
|
◇After an average of 5.5 months after the procedure, the results show that pain is reduced and joint function is improved
The Institute of Arthology at Himchan Hospital conducted a survey of 25 patients who received autologous platelet-rich plasma intraarticular injection therapy for about five months from January to June 4, 2025. The average age of the patient was 59.9 years, consisting of 20 women and 5 men. They were evaluated for joint pain and function at an average of 5.5 months after the procedure.
As a result, the Visual Analysis Scale (VAS) score, which represents the degree of pain, decreased significantly from an average of 5.88 points before the procedure to 2.91 points after the procedure. The VAS score is an expression of the intensity of pain felt by the patient from 0 to 10, which means that the higher the score, the more severe the pain.
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, an indicator of joint function evaluation, also improved significantly from an average of 41.04 points before the procedure to 26.16 points after the procedure. △Pain level △ Walking ability △ Up and down stairs △ Knee movement △ Daily life ability, etc., WOMAC is measured from 0 to 96, and the lower the score, the healthier the joint. In addition, the quality of life and treatment satisfaction felt by the patient themselves after the procedure were 2.79 out of 4 points and 3 points, respectively.
Lee Dong-nyeong, head of Himchan Hospital (Orthopedic Surgeon), said "Based on actual patient data and analyzing changes in pre- and post-procedure conditions, we can expect that self-platelet-rich plasma intra-articular injection treatment will have a positive effect on patients' quality of life as well as alleviating knee pain and improving joint function."
◇ Same-day procedure in the outpatient clinic without hospitalization, return to daily life
Autologous platelet-rich plasma intra-articular injection is a method of collecting 20 to 30mL of the patient's peripheral blood, centrifuging it, and injecting autologous platelet-rich plasma into the knee joint cavity. Because the patient's own blood is used, the risk of side effects or rejection is low. In addition, treatment is performed only by injection without incision or surgery, so it can be treated in an outpatient clinic without the need to be hospitalized. After the same day's procedure, you can quickly return to your daily life, relieving patients of time and cost.
Increasing platelet activity during autologous platelet-rich plasma intraarticular injection is known to help the therapeutic effect, so many studies are being conducted in this regard.
In particular, Himchan Hospital is studying and using the patented platelet activation device 'Proact Plus (PRO ACT+)' in collaboration with the manufacturer. Since this instrument activates platelets using the principle of natural activation in a physical way without adding a chemical activator, it can lower the risk of side effects caused by chemical methods. The organization was approved by the Ministry of Food and Drug Safety in early 2024, and Himchan Hospital is currently the only orthopedic hospital in Korea.
Lee Dong-nyeong, head of the medical center, said "Since self-platelet-rich plasma intra-articular injection has strict standards for treatment, it is important to carefully judge the suitability of treatment through sufficient consultation with your doctor." The condition of each patient should be assessed in detail"In the future, Himchan Hospital will continue to objectively verify the effectiveness of the procedure through various studies and strive to provide safe and reliable treatment to patients."
|
This article was translated by Naver AI translator.
